Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Calgary
With
Neuroscience Canada
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age between 18 and 60 years, the lower age limit has been set for safety purposes to avoid exposing children and adolescents to unproven therapies at least early in their development, the upper limit is set because the specificity of the diagnosis of ON is likely reduced in older individuals
onset of ON within the previous 30 days
intention to continue current multiple sclerosis (MS) disease modifying therapy (if any) for at least 6 months (glatiramer acetate, interferon beta) and not start, or switch to, a new therapy
sexually active participants of child-bearing potential must agree to use adequate contraception
willingness to provide written informed consent
You may not be if
Coexistence of any disease other than MS that could be responsible for ON or better explains their signs and symptoms. This would include patients with other suspected or established causes of vision loss including glaucoma, maculopathies, amblyopia, neuro-myelitis optica (NMO), and other optic neuropathies
clinically significant liver, renal, or bone marrow dysfunction
any condition that could interfere with any evaluation in the study including patients who are unable to undergo reliable OCT testing due to dense media opacities or severe nystagmus in whom appropriate fixation cannot be attained
concurrent or prior use of corticosteroids during this episode of optic neuritis
concurrent participation in any clinical therapeutic trial
use within the previous 12 months of any of the following: natalizumab, mitoxantrone, cyclophosphamide, azathioprine, cyclosporine, methotrexate, or any other immunomodulating or immunosuppressive drug including other recombinant or non-recombinant cytokine or any experimental therapy known to effect immune function
use within the previous 6 months of minocycline or another tetracycline or use of either for MS at any time
any other condition or situation that in the opinion of the investigator would either put the patient at risk of worsening health if enrolled in the trial or would prevent completion of the trial with complete follow-up.
